Alzheimer’s disease biomarkers in cerebrospinal fluid are stable with the Elecsys immunoassay to most pre-analytical influencing factors except freezing at -80 °C

Table 1 Demographic data and baseline Alzheimer´s disease cerebrospinal fluid (CSF) biomarker concentrations

Characteristic	Patients (n = 29)
Demographic data
Females:males	15:14
Age [years], median (min-max)	53 (20–83)
Diagnosis	MDD (n = 14), epilepsy (n = 3), ADHS (n = 2), ALS, amnestic syndrome, bipolar affective disorder, CIDP, generalized anxiety disorder, headache (unspecified), M. Parkinson (idiopathic), MS, PTSD, polyneuropathy (non-inflammatory) (each n = 1)
CSF biomarker baseline concentrations
Aß42 [pg/ml], mean (min-max)	1,349 (484-2,500)
P-tau [pg/ml], mean (min-max)	15.7 (8–50)
T-tau [pg/ml], mean (min-max)	193.4 (80–598)
P-tau/Aß42 concentration quotient, mean (min-max)	0.01 (0.006–0.05)
T-tau/Aß42 concentration quotient, mean (min-max)	0.162 (0.0796–0.654)

AD = Alzheimer´s disease, CSF = cerebrospinal fluid, Aß42 = Amyloid beta 1–42, P-tau = Phospho-Tau (181P), T-tau = Total-Tau, MDD = major depressive disorder, ADHS = attention-deficiency-hyperactivity syndrome, ALS = amyotrophic lateral sclerosis, CIDP = chronic inflammatory demyelinating polyneuropathy, MS = multiple sclerosis, PTSD = post-traumatic stress disorder

ISSN: 2524-3489